about
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplaAll-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.Central venous catheter-related infections in hematology and oncology : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation.Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.Bilateral thalamic infarction after reinfusion of DMSO-preserved autologous stem-cells.The effects of rituximab treatment during pregnancy on a neonateHu-antibody positive limbic encephalitis in a patient with Hodgkin lymphomaAdministration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pProspective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98AGranulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma
P50
Q33375805-8460F369-DBD6-4E0A-8D13-2E0D54CEFC2BQ33417762-A8A80218-2667-4320-B101-D20298D71B70Q33443001-AC170752-EB83-4294-BA63-0C3D21D9F1A9Q33558161-98DD150F-BAF6-447A-9B90-51871B6C0B5CQ35298777-7544A317-4203-4FB8-B678-2814C5E66E84Q35800851-D201A624-1BC6-40D4-B539-32C2159EC93BQ35881063-F053C034-E9C4-4EB3-9359-6AE67E2E2CF4Q35999062-DE0CB34D-5274-48EE-9499-89BA309914F3Q36151586-D5B5D13A-A5B7-4202-A321-B6A16421BB23Q37217395-7B935E73-D624-46D5-93FF-5773BF5D5369Q38207933-0E10EDD1-7F53-4CFB-BEE6-6E8270BAFDF8Q38859426-F30452D1-6C05-443C-B7F9-2A9B882D188EQ40751642-CA2DB259-1F85-4622-8C8D-7F21404B2023Q41230411-2C33C66C-285D-4F77-891C-6BE892871DE9Q42335813-AE3EAC30-6AE1-4970-9711-A47FEE372804Q47143616-8F0F35EC-CF42-44CA-8C65-C888E5D93471Q47899730-C7890230-4135-420F-9604-55EC225DB413Q48369137-25E169A8-47F7-42F1-A8D6-185B86697952Q80236650-DB8EE96E-0E78-49E3-9CE1-B5162BE4F7ACQ82820729-EBD79569-DB56-4F24-BB31-5AD1746A1B87Q82907285-5FC1E77A-AFD0-4DC0-B0A9-464954694C15Q84967864-F462C539-62BD-41F4-A373-29BF93ED875DQ87808223-7647EEB4-6B89-433E-86C8-2C742C4C1478
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hans Salwender
@ast
Hans Salwender
@en
Hans Salwender
@es
Hans Salwender
@nl
type
label
Hans Salwender
@ast
Hans Salwender
@en
Hans Salwender
@es
Hans Salwender
@nl
prefLabel
Hans Salwender
@ast
Hans Salwender
@en
Hans Salwender
@es
Hans Salwender
@nl
P106
P214
3948147553271453800005
P31
P496
0000-0001-7803-0814
P735
P7859
viaf-3948147553271453800005